HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Novel lytics, novel imaging: a new treatment strategy in stroke?

Abstract
Intravenous thrombolysis with alteplase is one of the few evidence-based acute ischemic stroke treatments. Efficacy is time dependent and not all patients treated within the 4.5 h license derive benefit. The lytic agent tenecteplase has theoretical benefits. In the Phase II study by Parsons and colleagues, tenecteplase was superior to alteplase across imaging and safety outcomes for patients selected using specific imaging criteria. We review the evidence for thrombolysis, experience with tenecteplase and compare this study with others that have used similar designs for the investigation of novel stroke lytic agents.
AuthorsTerence J Quinn, Jesse Dawson
JournalJournal of comparative effectiveness research (J Comp Eff Res) Vol. 1 Issue 4 Pg. 311-4 (Jul 2012) ISSN: 2042-6313 [Electronic] England
PMID24237464 (Publication Type: Journal Article, Comment)
Chemical References
  • Fibrinolytic Agents
  • Tissue Plasminogen Activator
Topics
  • Brain Ischemia (drug therapy)
  • Female
  • Fibrinolytic Agents (therapeutic use)
  • Humans
  • Male
  • Stroke (drug therapy)
  • Tissue Plasminogen Activator (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: